Skip to main content
SpringerLink
Log in
Book cover

Cancer Treatment An Update pp 146–149Cite as

A Phase II study of 2-weekly high-dose Epirubicin with r-met-hu G-CSF in advanced breast cancer

  • Conference paper

  • 72 Accesses

Abstract

Forty-one patients with advanced breast cancer were treated with high-dose epirubicin every 2 weeks with r-met-hu G-CSF. This intensified regimen was highly active and well tolerated.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fountzilas G, Inone S, Ohnuma T (1990) Schedule-dependent interaction of Cytarabine plus Doxorubicin or Cytarabine plus mitoxantrone in acute myelogenic leukemia cells in culture. Leukemia 4: 321–324

    PubMed  CAS  Google Scholar 

  2. Wheeler RH, Ensminger WD, Thrull JH et al (1982) High-dose Doxorubicin: An exploration of the dose-response curve. Cancer Treat Rev 66: 493–498

    CAS  Google Scholar 

  3. Fountzilas G, Skarlos D, Pavlidis N et al (1991) High-dose Epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Cooperative Oncology Group Study. Tumori 77: 232–236

    PubMed  CAS  Google Scholar 

  4. Carmo-Pereira J, Costa FO, Henriques E et al (1987) A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56: 471–473

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Hortobagyi GN, Bodney GP, Buzdar AU et al (1987) Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5: 354–364

    PubMed  CAS  Google Scholar 

  6. French Epirubicin Study Group (1991) A prospective randomized trial comparing Epirubicin monochemotherapy to two Fluorouracil, Cyclophosphamide, and Epirubicin regimens differing in Epirubicin dose in advanced breast cancer patients. J Clin Oncol 9: 305–312

    Google Scholar 

  7. Habeshaw T, Paul J, Jones E et al (1991) Epirubicin at two dose levels with prednisone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 9: 295–304

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AHEPA Hospital, Aristote University, Thessaloniki, Macedonia, Greece

    G. Fountzilas, D. Skarlos, T. Giannakakis, A. Athanasiades, D. Bafaloukos, J. Protopsaltis, M. Beer, N. Pavlidis & P. Kosmidis

  2. « Agii Anargiri » Cancer Hospital, Athens, Greece

    G. Fountzilas, D. Skarlos, T. Giannakakis, A. Athanasiades, D. Bafaloukos, J. Protopsaltis, M. Beer, N. Pavlidis & P. Kosmidis

  3. « METAXA » Cancer Hospital, Piraeous, University of Ioannina, Ioannina, Greece

    G. Fountzilas, D. Skarlos, T. Giannakakis, A. Athanasiades, D. Bafaloukos, J. Protopsaltis, M. Beer, N. Pavlidis & P. Kosmidis

Authors
  1. G. Fountzilas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Skarlos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Giannakakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Athanasiades
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Bafaloukos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Protopsaltis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Pavlidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Kosmidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hôpital Saint-Louis, 1, avenue Vellefaux, 75475, Paris Cedex 10, France

    P. Banzet

  2. The Mount Sinai Medical Center, 1 G. Levy Place, New York, NY, 10029-6574, USA

    J. F. Holland

  3. Service d’Oncologie Médicale, Hôpital Pitié-Salpétrière Pavillon Jacquart, 47, boulevard de l’Hôpital, 75651, Paris Cedex 13, France

    D. Khayat

  4. Hôpital Pitié-Salpétrière Pavillon Jacquart, 47, boulevard de l’Hôpital, 75651, Paris Cedex 13, France

    M. Weil

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag France

About this paper

Cite this paper

Fountzilas, G. et al. (1994). A Phase II study of 2-weekly high-dose Epirubicin with r-met-hu G-CSF in advanced breast cancer. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Cancer Treatment An Update. Springer, Paris. https://doi.org/10.1007/978-2-8178-0765-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0765-2_27

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0767-6

  • Online ISBN: 978-2-8178-0765-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation